No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma

Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer

“…No difference in genotype frequencies was found between NSCLC patients and controls, but the number of subjects studied in each group was probably too small to draw a conclusion since our study was not primarily designed to evaluate this question. Concerning MMP-9 gene polymorphism, our results are in agreement with a recent case-control study that also showed that −1562C/T MMP-9 genotype distributions were similar in NSCLC patients and controls [19]. Intriguingly, the MMP-9 −1562C allele was more frequent in patients with squamous cell carcinoma than in controls (p = 0.018), suggesting it might favour the development of this histological subtype.…”

“…On the other hand, in agreement with previous studies on breast cancer or epithelial cells in culture [12][13][14][15][16][17][18][19][20][21][22][23][24], expression of the MMP-9 gene does not appear to be influenced by the −1562C/T SNP according to the results obtained in NSCLC and non-affected lung tissues. However, the −1562T MMP-9 allele has been shown to decrease the capacity of a putative repressor protein to bind to the MMP-9 promoter, with a subsequent increase in gene transcription in culture macrophages [10].…”

“…Intriguingly, the MMP-9 −1562C allele was more frequent in patients with squamous cell carcinoma than in controls (p = 0.018), suggesting it might favour the development of this histological subtype. On the other hand, our findings do not demonstrate that the C alleles of −1306C/T and −735C/T MMP-2 polymorphisms enhance the susceptibility to develop lung cancer, as recently demonstrated, particularly in heavy smokers [9][10][11][12][13][14][15][16][17][18][19][20]. Several hypotheses can explain this apparent discrepancy.…”

MMP2 promoter polymorphism (C‐1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation

“…Price et al (20) reported that MMP2 TT individuals express lower levels of MMP2 enzyme in both stromal and neoplastic cells as a result of the lower promoter activity of the T allele. However, the implications of MMP9 C-1562T polymorphisms in carcinogenesis and progression vary greatly in different types of human malignancy (27,(31)(32)(33)(34)(35). Further studies also showed the relationship between the MMP2 levels of tissue and plasma and the C-1306T polymorphisms.…”

Clinical implications of matrix metalloproteinase‐1, ‐3, ‐7, ‐9, ‐12, and plasminogen activator inhibitor‐1 gene polymorphisms in colorectal cancer

“…A recent study showed that the allele frequency of the MMP9–1562C > T polymorphism in gastric cancer patients was similar to that in healthy controls, but the MMP9‐1562 * T allele was significantly associated with an invasive phenotype in gastric cancer 18 . Otherwise, it has been reported that the genotype and allele distributions of MMP9–1562C > T did not show significant influence both occurrence and lymphatic metastasis of non‐small cell lung carcinoma 32 . Together with our findings, this result suggests that the transcriptional activity enhanced by the MMP9‐1562 * T allele does not seem to be crucial for gastric and colorectal tumorigenesis.…”